CCHT(SZ:000661) Sou Hu Cai Jing·2025-12-08 14:25Core Viewpoint - Changchun High-tech (000661) has seen its stock price decline by 0.53% to 99.2 yuan, with a total market capitalization of 40.467 billion yuan as of December 8, 2025. The company announced that two of its products have been included in the National Medical Insurance Directory, which is expected to enhance their market potential and revenue streams [1]. Group 1 - Changchun High-tech's stock opened at 100.07 yuan, reached a high of 100.45 yuan, and a low of 99.02 yuan on the same day, with a trading volume of 5.43 billion yuan and a turnover rate of 1.37% [1]. - The company’s subsidiary, Jinsai Pharmaceutical, has received approval for its self-developed product, Jin Pei Sheng Growth Hormone Injection (brand name: Jin Sai Zeng), and the co-introduced product, Acetate Medroxyprogesterone Oral Suspension (brand name: Mei Shi Ya), to be included in the National Medical Insurance Directory [1]. - Jin Pei Sheng is specifically indicated for children with growth retardation due to endogenous growth hormone deficiency, while Mei Shi Ya is indicated for weight loss in AIDS patients with anorexia and cachexia [1]. Group 2 - The reimbursement standards for these newly included drugs will be effective from January 1, 2026, to December 31, 2027, with the new directory set to be implemented starting January 1, 2026 [1].